RANDOMISATION, BIAS AND BLINDING IN CLINICAL TRIALS Dipesh Mistry & Jessica Smith September 2010.

Slides:



Advertisements
Similar presentations
Agency for Healthcare Research and Quality (AHRQ)
Advertisements

Biometrics India, Pfizer Global R & D
Use of Placebos in Controlled Trials. Background The traditional ‘double-blind’ RCT uses a placebo to conceal allocation. There are a number of advantages.
DESIGNING EXPERIMENTS
Designing Clinical Research Studies An overview S.F. O’Brien.
Section 3.2: Experiments in the Real World
Observational Studies and RCT Libby Brewin. What are the 3 types of observational studies? Cross-sectional studies Case-control Cohort.
Clinical trials Introduction.
Introduction Clinical trials Why clinical trials? The Clinical Trial Process Informed consent Patients‘ interests Rights and protection Trials Registers.
KINE 4565: The epidemiology of injury prevention Randomized controlled trials.
Section 1.3 Experimental Design © 2012 Pearson Education, Inc. All rights reserved. 1 of 61.
Section 1.3 Experimental Design.
Why to Randomize a Randomized Controlled Trial? (and how to do it) John Matthews University of Newcastle upon Tyne.
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
A brief introduction to randomisation methods Peter T. Donnan Professor of Epidemiology and Biostatistics.
Copyright © 2010, 2007, 2004 Pearson Education, Inc. Chapter 13 Experiments and Observational Studies.
Elements of a clinical trial research protocol
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Allocation Methods David Torgerson Director, York Trials Unit
Basics of Study Design Janice Weinberg ScD
Basics of Study Design Janice Weinberg ScD Professor of Biostatistics Boston University School of Public Health.
Clinical Trials Hanyan Yang
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Chapter 5 Data Production
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Chapter 1: Introduction to Statistics
Clinical Trials 2015 Practical Session 1. Q1: List three parameters (quantities) necessary for the determination of sample size (n) for a Phase III clinical.
Copyright © 2010 Pearson Education, Inc. Chapter 13 Experiments and Observational Studies.
Experiments and Observational Studies. Observational Studies In an observational study, researchers don’t assign choices; they simply observe them. look.
Copyright © 2007 Pearson Education, Inc. Publishing as Pearson Addison-Wesley Chapter 13 Experiments and Observational Studies.
What is a Clinical Trial (alpha version) John M. Harris Jr., MD President Medical Directions, Inc.
Introduction to Clinical Trials
Experimental Design 1 Section 1.3. Section 1.3 Objectives 2 Discuss how to design a statistical study Discuss data collection techniques Discuss how to.
Slide 13-1 Copyright © 2004 Pearson Education, Inc.
Chapter 5: Producing Data “An approximate answer to the right question is worth a good deal more than the exact answer to an approximate question.’ John.
LT 4.2 Designing Experiments Thanks to James Jaszczak, American Nicaraguan School.
Basics of Randomization.
Randomization & Blinding Dr. Aparna Walanj Clinical Research Head Ethika Clinical Research Center.
Lecture 5 Objective 14. Describe the elements of design of experimental studies: clinical trials and community intervention trials. Discuss the advantages.
Chapter 3.1.  Observational Study: involves passive data collection (observe, record or measure but don’t interfere)  Experiment: ~Involves active data.
Adaptive randomization
Introduction Clinical trials Why clinical trials? Process of a clinical trial Informed consent Patients‘ interests Rights and protection Study Registers.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
Gathering Useful Data. 2 Principle Idea: The knowledge of how the data were generated is one of the key ingredients for translating data intelligently.
EXPERIMENTAL EPIDEMIOLOGY
The Practice of Statistics, 5th Edition Starnes, Tabor, Yates, Moore Bedford Freeman Worth Publishers CHAPTER 4 Designing Studies 4.2Experiments.
1 Health and Disease in Populations 2002 Session 8 – 21/03/02 Randomised controlled trials 1 Dr Jenny Kurinczuk.
Section 1.3 Experimental Design.
Penn CTSI Research Seminar Clinical Trials November 10, 2015 Vernon M. Chinchilli, PhD Distinguished Professor and Chair Department of Public Health Sciences.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Making Randomized Clinical Trials Seem Less Random Andrew P.J. Olson, MD Assistant Professor Departments of Medicine and Pediatrics University of Minnesota.
Chapter 6 Designing Experiments. Section 6.2 Experiments in the Real World.
1 Chapter 11 Understanding Randomness. 2 Why Random? What is it about chance outcomes being random that makes random selection seem fair? Two things:
European Patients’ Academy on Therapeutic Innovation Blinding in clinical trials.
Critical Appraisal Course for Emergency Medicine Trainees Module 3 Evaluation of a therapy.
A brief introduction to randomisation methods
Welcome Clinical Trials October 11, 2016 Vernon M. Chinchilli, PhD
CHAPTER 4 Designing Studies
Probability and Statistics
Randomized Trials: A Brief Overview
The 4th ICTMC & 38th Annual Meeting of SCT
Experiments and Observational Studies
Chapter 4: Designing Studies
RCT Workshop, Bushehr 2/16/2019.
Statistical Reasoning December 8, 2015 Chapter 6.2
Biometrics India, Pfizer Global R & D
Evidence Based Practice
Warmup A drug company wants to test a new drug, statsium, to determine if it improves memory in young adults. There will be two treatments: a daily.
Probability and Statistics
Presentation transcript:

RANDOMISATION, BIAS AND BLINDING IN CLINICAL TRIALS Dipesh Mistry & Jessica Smith September 2010

OVERVIEW Randomisation -What, why, how and when Allocation Concealment Bias Blinding

WHAT IS RANDOMISATION? DEFINITION Randomisation is a process by which each participant has the same chance of being randomly assigned to one of two or more groups e.g. Group A & Group B.

WHY RANDOMISE? Possible explanations for a difference would include: 1.the intervention exhibits a real effect; 2.the outcome difference is solely due to chance 3.there is a systematic difference (bias) between the groups due to factors other than the intervention Eligible patients Group A Group B Allocate Patients Analysis Follow up

WHAT IS ALLOCATION BIAS? LBP Patients Less Severe Patients More Severe Patients

WHAT IS ALLOCATION BIAS? Is there a difference because: -the treatment actually works -of the way he has allocated patients

RANDOMISATION DEPENDS ON: 1.the generation of an unpredictable allocation sequence 2. the concealment of that sequence

ALLOCATION RATIO’S 1.Equal Allocation Participants have the same chance of being assigned to trial arms Easily accommodates multiple arm studies Generally the most efficient design Easy to implement 2. Unequal Allocation Assigns more participants to intervention e.g. BEST – 2:1 allocation

TYPES OF RANDOMISATION Simple Randomisation Permuted Block Randomisation Stratified Block Randomisation Minimisation Method

SIMPLE RANDOMISATION Definition Most basic form of randomisation where each treatment assignment is ”memory less” - made without regard to previous assignments Some examples: Unbiased coin toss for each trial participant Roll an unbiased die Sequence of Random Numbers from statistical textbooks Computer generated random sequence

ILLUSTRATION Two Groups (criteria: {2,4,6,8,0}=A, {1,3,5,7,9}=B): A computer generated random sequence: 4,8,3,2,7,2,6,6,3,4,2,1,6,2,0,…… AABABAAABAABAAB

ILLUSTRATION A computer generated random sequence: 4,8,3,2,7,2,6,6,3,4,2,1,6,2,0,……. Two Groups: different randomisation ratios (e.g. 1:2) (criteria:{1,2,3}=A, {4,5,6,7,8,9}=B; ignore 0’s) BBAABABBABAABA-

ILLUSTRATION A computer generated random sequence: 4,8,3,2,7,2,6,6,3,4,2,1,6,2,0,……. Three Groups: (criteria:{1,2,3}=A, {4,5,6}=B, {7,8,9}=C; ignore 0’s) BCAACABBABAABA-

SIMPLE RANDOMISATION SUMMARY Pros and Cons + Simplistic implementation + Allocation is random and unpredictable − Can produce unbalanced allocation − Can lead to analysis complications e.g. interim analyses Imbalance Solution Replace with another allocation list (criteria: >10) Restrict the randomisation

BLOCK/PERMUTED BLOCK RANDOMISATION Definition Allocation list is comprised of “blocks” Each block contains one possible combination (permutation) of possible treatment allocations Allocation is balanced at end of each block

Basic Implementation 1 Block size is an multiple of treatment arms i.e. 2 arms → b = {2, 4, 6,...}, 3 arms → b = {3, 6, 9,...} 2 List all possible combinations e.g. For block size of 2: AB or BA 3 Choose a criteria for each block of patients Digits 0-4 = ABDigits 5-9 = BA ABBAAB BAABBA AB BAAB 4,8,3,2,7,2,6,6,3,4,2,1,6,2,0,…….

ILLUSTRATION 1 Lets say:- want to compare 2 groups e.g. Grp A & Grp B - choose block size of 4 patients 2 List allocation combinations for block size of 4 AABB BAAB ABBA ABAB BABA BBAA 3 Choose criteria for each block of patients 1 - AABB2 - BAAB3 - ABBA 4 - ABAB5 - BABA6 – BBAA ignore 0,7,8, … -- 4,8,3,2,7,2,6,6,3,4,2,1,6,2,0,……. ABABABBABAAB BBAA …

BLOCK RANDOMISATION SUMMARY Pros and Cons + Balance between arms is guaranteed by block’s end + Interim analysis can still have balance − Bias can occur if allocation sequence is determined Recommendations Do NOT use block size of 2 Use reasonably large blocks to avoid predictability Not too large if interim analysis intended

STRATIFIED BLOCK RANDOMISATION Definition Balancing treatment groups with respect to prognostic factors which may be related with participant response in order to prospectively achieve treatment group comparability

WHAT DOES THIS MEAN? REMEMBER: randomisation is to ensure treatment group comparability HOWEVER: certain prognostic factors may be predictors of response e.g. age, sex, THEREFORE: we want to make certain that there is a balance in both groups for these factors HOW? – have a separate block randomisation scheme for each category

ILLUSTRATION Single Strata: Age, (block size 4) AGE <50BABAAABBABBABBAABAAB… AGE ≥50BAABABBABBAAABABBABA… GROUP AGROUP B AGE <50 50% AGE ≥50 50%

ILLUSTRATION Two Strata: Gender & Age, (block size 4) MaleAGE <50BABAAABBABBABBAABAAB… MaleAGE ≥50BABAAABBABBABBAABAAB… FemaleAGE <50BAABABBABBAAABABBABA… FemaleAGE ≥50BAABABBABBAAABABBABA… GROUP AGROUP B MaleAGE <5050% MaleAGE ≥5050% FemaleAGE <5050% FemaleAGE ≥5050%

STRATIFIED RANDOMISATION SUMMARY Pros and Cons + Balance important variables between arms + Improves power by reducing variance − Complicates allocation process − Too many strata can lead to sparse data

MINIMISATION METHOD Definition Minimisation (Adaptive randomisation) is an accepted statistical method to limit imbalance in randomised clinical trials in conditions with known important prognostic factors. Its called minimisation because imbalance in the prognostic factors is minimised

ILLUSTRATION - Lets say we have 40 patients already - Each factor (gender & age) should consist of 40 patients - Next patient (41 st patient) is Female and <50. - For each treatment, add number of patients in the corresponding 2 rows: Group A = = 17 Group B = = 15 FactorLevelGROUP AGROUP B GenderMale1112 Female98 AgeAGE <5087 AGE ≥ NEXT ASSIGNMENT TO GROUP B

MINIMISATION METHOD SUMMARY Pros and Cons + Cannot determine next allocation + Maintains balance across groups + Advantage over stratified block randomisation, as randomisation does not occur within strata − Can be technically challenging to implement

ALLOCATION CONCEALMENT - different to blinding - avoids selection bias Trial TypeMechanism Single-centre trial-Independent person responsible for patients registration and randomization - Use randomisation list or sealed envelopes Multi-centre TrialAfter gaining consent from eligible patient: -Central randomisation by telephone -Interactive voice response system -Fax or internet Central registration office not feasible/desirable -Sealed envelopes containing treatment allocation inside

PRACTICAL CONSIDERATIONS STUDY TYPERANDOMISATION Small studiesBlock Large studiesBlock Large, Multi-centre studiesStratified Block / Minimisation Large, prognostics factorsMinimisation

RECAP Randomisation -Reduces allocation bias -Ensures comparability of Groups Allocation Concealment -Reduces selection bias -Again, ensures comparability of Groups OTHER FORMS OF BIAS AFTER RANDOMISATION….

TYPES OF BIAS Patient bias Care Provider bias Assessor bias Analysis and Interpretation bias

PATIENT BIAS DEFINITION The patients knowledge of the treatment being received may affect the outcome of the study. patient’s knowledge that they are receiving a “new” treatment may substantially affect the patient’s subjective assessment.

CARE PROVIDER BIAS DEFINITION The care provider’s knowledge of which treatment a patient is receiving may affect the way the provider Deals with the patient Treats the patient May give patient information about the treatment the patient is receiving

ASSESSOR BIAS DEFINITION Assessor’s knowledge of which treatment the patient is receiving may affect the way the assessor assesses outcome Affect validity of conclusion of the study If assessment conducted whilst patient still receiving treatment may indirectly provide patient with information about the treatment they are receiving.

ANALYSIS AND INTERPERTATION BIAS Knowledge of the treatment arm may affect resultant analysis of the data as Seeking explanation of an “anomalous” finding when one is found contrary to the study hypothesis. Accept a “positive” finding without fully exploring the data Knowledge of the treatment arm may affect decisions made by external monitors Terminate the study due to adverse events Terminate the study for superiority of treatment

BLINDING Blinding = masking treatment All of these potential biases can be avoided if everyone involved within a study is blinded to the treatment being given to the patient. HIERARCHY OF BLINDING Un-blinded Single Blind Double Blind Complete Blind

SINGLE BLIND The patient (or sometimes the clinician) is blinded to the treatment given. Often used when double blinding is impractical for reason such as Need to adjust medication Potential side effects

DOUBLE BLIND Neither the participant nor the physician conducting the study know which treatment is being given to the participant Minimises both potential patient biases and potential assessor biases Should be used whenever possible

DOUBLE BLINDING TECHNIQUES Placebo for each possible treatment Tablets identical in physical appearance Tablets with similar taste and smell Same carrier used for IV infusions Other treatments “shammed” as far as possible Sham surgery

DOUBLE BLINDING- ALWAYS FEASIBLE? Double blinding may not be possible: May not be ethically permissible to blind patient Study using an exercise intervention

PROBLEMS WITH DOUBLE BLINDING SIDE EFFECTS If drug produces side effects = difficult to blind patient and ethically wrong to produce a placebo that induces side effects. EFFICACY If treatment truly effective may become clear as to which treatment the patient is receiving – rare!

COMPLETE BLINDING Effectively it is the best approach BUT Requires two groups of people for data processing, one group to encode data and one group to perform the analysis. Therefore not economically feasible. Used sometimes by major drug companies

COMPLETE BLINDING TECHNIQUES Analysis uses coded treatment groups Analysis uses coded side effects Analysis uses coded laboratory tests

SUMMARY BIAS different types of bias exist in all clinical trials Randomisation deals with Allocation concealment deals with Blinding deals with other types of bias Allocation bias Selection bias

THANK YOU FOR LISTENING ANY QUESTIONS?

Next week… BY:Janet Dunn & Louise Hiller DATE:Thursday 30 th September TIME: pm ROOM:T0.08/09 ANALYSIS Simple and to the point, defining terms